Surveys - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles:
9%
Greater adoption of continuous manufacturing:
9%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals:
27%
The rise of biologic-based drugs in commercial product portfolios and pipelines:
45%
Greater adoption of the preferred provider model in outsourcing:
9%
Other Surveys
Negative impacts on drug development
Pharmaceutical business challenges
Reason for seeking new position
Salary Satisfaction
Changing jobs
Job security
QbD in sterile manufacturing
Regulatory Challenges
INTERPHEX 2013
Biosimilars
US Biotechnology Hubs
Regulatory Enforcement
Trade Shows
Patent Cliff
FDA confidentiality
Preventing counterfeiting
European Pharmacovigilance Activities
Generic Drug User Fees Amendments of 2012
European Legislation
Drug Settlements
Emerging Markets
Energy Efficiency
Affordable Care Act
Energy Efficiency
Drug Shortages
Transparency
Quality Management
Analytical equipment
DTC Advertising
Biologics Manufacturing
Powder properties
Sterile manufacturing
Social media
API Manufacturing
Lyophilization Advances
Injection technologies
Oral drug delivery
Generic-Drug User Fees
Innovation in Solid Dosage
Small-Molecule API Outsourcing
USP Monographs
Anticounterfeiting Solutions
FDA's Enforcement Strategy
Quality by Design and APIs
Outsourcing Biologics
FDA Biosimilars Pathway
High-potency APIs
Biosimilars
Emerging markets
Carbon footprints
Needleless devices
BioPharm Quick Poll
BioPharm Survey :: Involvement In the Biopharmaceutical Industry

ADVERTISEMENT

ADVERTISEMENT

Click here